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Background: Hepatoblastoma (HB) is the most common primary, malignant pediatric liver tumor in children. The
treatment results for affected children have markedly improved in recent decades. However, the prognosis for
high-risk patients who have extrahepatic extensions, invasion of the large hepatic veins, distant metastases and very
high alpha-fetoprotein (AFP) serum levels remains poor. There is an urgent need for the development of novel
therapeutic approaches.
Methods: An attenuated strain of measles virus, derived from the Edmonston vaccine lineage, was genetically
engineered to produce carcinoembryonic antigen (CEA). We investigated the antitumor potential of this novel viral
agent against human HB both in vitro and in vivo.
Results: Infection of the Hep2G and HUH6 HB cell lines, at multiplicities of infection (MOIs) ranging from 0.01 to 1,
resulted in a significant cytopathic effect consisting of extensive syncytia formation and massive cell death at
72–96 h after infection. Both of the HB lines overexpressed the measles virus receptor CD46 and supported robust
viral replication, which correlated with CEA production. The efficacy of this approach in vivo was examined in murine
Hep2G xenograft models. Flow cytometry assays indicated an apoptotic mechanism of cell death. Intratumoral
administration of MV-CEA resulted in statistically significant delay of tumor growth and prolongation of survival.
Conclusions: The engineered measles virus Edmonston strain MV-CEA has potent therapeutic efficacy against HB cell
lines and xenografts. Trackable measles virus derivatives merit further exploration in HB treatment.
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Hepatoblastoma (HB) is the most common primary, ma-
lignant liver tumor in children with an incidence of 0.7–1
case per million children [1-4]. The median age at diagno-
sis is 18 months; only 5% of the tumors are diagnosed
after 4 years of age [5].
Although treatment strategies against HB have been
established, they are constantly evaluated and revised
through cooperative study groups worldwide [6-8]. The
treatment results for affected children have markedly
improved over the last decades due to the evolution of
therapy from consisting of surgery alone to involving a* Correspondence: zhangshucheng76@126.com
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reproduction in any medium, provided the ormultimodal approach that combines adjuvant chemo-
therapy regimens and surgery. Recent international clin-
ical studies have focused on the risk-adapted treatment
of standard-risk patients with potentially resectable
tumors and high-risk patients with unresectable tumors
associated with extrahepatic extensions, invasion of the
large hepatic veins, distant metastases and very high
alpha-fetoprotein (AFP) serum-levels [2-4]. To date,
about 92% of the patients in the standard-risk group can
be cured by combining neo-adjuvant chemotherapy and
surgery, whereas approximately 60% of all high-risk
patients survive [2-4]. One problem that is especially
present in the latter group is multidrug resistance after a
number of chemotherapy courses [1,5]. Thus, the imple-
mentation of new, efficient drugs into future therapeutic
regimens is especially critical.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Zhang et al. BMC Cancer 2012, 12:427 Page 2 of 10
http://www.biomedcentral.com/1471-2407/12/427Oncolytic therapy, which uses replication-competent
viruses that replicate in the tumor cells and kill the cells
lytically has limited side effects. This therapy has shown
great potential in the treatment of multiple tumors such
as lymphoma, ovarian cancer, mesothelioma, breast can-
cer, renal and hepatocellular carcinoma [9-15]. A large
variety of oncolytic viruses have been engineered [16-22].
Among the many oncolytic virus systems, the attenuated
Edmonston vaccine strain of the measles virus (MV-Edm)
has proven safe and effective [23-27]. It exerts its cyto-
pathic effect (CPE) by fusing infected cells with the
surrounding cells, forming multinucleated syncytia, which
is followed by cell death by apoptotic or nonapoptotic
mechanisms [24,26,28]. MV is a negative-strand RNA
paramyxovirus, and it has been shown that MV-Edm
preferentially fuses and kills cells overexpressing the CD46
receptor [29]. CD46 is a membrane-associated comple-
ment regulatory protein that is ubiquitously expressed on
nucleated human cells [30,31]. Tumor cells frequently
overexpress CD46 [32]. These mechanisms contribute to
the tumor selectivity of MV-Edm.
In contrast to the wild-type virus, which can cause a
potentially serious disease, the vaccine and the Edmon-
ston strains of the measles virus have an excellent safety
record, with millions of administered vaccine doses that
have significantly decreased the incidence, morbidity and
mortality of measles worldwide [33]. Another advantage
of using the MV-Edm as a vector is that the virus may
be effectively engineered to express soluble marker pep-
tides, such as CEA and beta-HCG, which may be
employed as real-time correlates of viral gene expression
in vivo. Furthermore, this virus expresses membrane
proteins, such as the sodium iodine symporter, which
allows for radionuclide imaging-based assessment of the
viral localization and spread over time [33,34]. The
serum CEA level has been used as an effective surrogate
of the viral gene expression, which correlates with viral
growth both in vivo and in vitro [33]. The detection of
CEA in serum is widely available through clinical assays.
Therefore, measuring the serum CEA is a cost-effective
method for monitoring viral gene expression after
MV-CEA treatment. Furthermore, this method allows for
repeated measurements with minimal risk to the patient.
In the current study, we evaluated the efficacy of re-
combinant MV-Edm that expresses the soluble extracel-
lular N-terminal domain of human CEA (MV-CEA)
against human HB cell lines and xenografts.
Methods
Cell culture
The human HB cell line Hep2G was obtained from the
American Type Culture Collection (ATCC; Manassas,
VA) and maintained in modified Eagle's medium (MEM)
supplemented with 10% heat-inactivated fetal bovineserum (FBS) and 1% sodium pyruvate. The HUH6 cell
line was kindly denoted by Professor Cai from the China
Medical University. The normal human liver cell line
L-02 was obtained from ATCC and maintained in MEM
supplemented with 10% heat-inactivated fetal bovine
serum (Sigma, Steinheim, Germany). The Vero African
green monkey kidney cells (ATCC, CCL-81) used for the
production of MV were maintained in DMEM supple-
mented with 5% FBS. All media used in this study con-
tained 100 U/ml penicillin-streptomycin. Growth media,
sera, and supplements were obtained from Gibco BRL
(Grand Island, NY). All cells used in this study were cul-
tured in a humidified atmosphere of 5% CO2 at 37°C.
Viruses and infection assays
The construction of MV-CEA was carried out in our la-
boratory as described previously [33]. The reverse genet-
ics system, described by Radecke was employed [35].
In summary, the NSe strain c-DNA infectious clone
(derived from the MV-Edm vaccine lineage Seed B) [36]
was engineered by inserting the human CEA gene up-
stream of the MV N gene. The titers of viral stocks were
determined by 50% endpoint dilution assays (TCID 50)
on Vero cells. For virus infection assays, 2 × 105 cells
were incubated with recombinant MV-Edm was diluted
in 1.0 ml of Opti-MEM (Life Technologies, Inc. Shang-
hai, China) for 2 hours at 37°C. At the end of the incu-
bation period, the virus was removed, and the cells were
maintained in standard medium.
Evaluation of CPEs in vitro
The Hep2G, HUH6 and L-02 cell lines were cultured in
24-well plates at a density of 2 × 105 cells/well. The cells
were infected with MV-CEA at a multiplicity of infection
(MOI) of 1 or 0.1 in 0.2 ml of Opti-MEMI (GIBCO,
Invitrogen, Shanghai, China) for 2 hours. The virus sus-
pension was removed, and 1 ml of fresh medium was
added to each well. At 96 hours after infection, the cells
were gently washed twice with phosphate buffered saline
(PBS), and the remaining cells were fixed with 0.5% glu-
taraldehyde in PBS for 15 minutes. Then, the cells were
washed with PBS and stained with 0.1% crystal violet
solubilized in 2% ethanol–distilled water. The stained
product was subsequently washed twice with distilled
water, air-dried, and then photographed.
Cell proliferation assay
The Cell-Titer 96 Aqueous Non-Radioactive Cell Prolif-
eration Assay (Promega, Madison, WI) was used in this
study. Hep2G, HUH6 and L-02 cell lines were plated in
96-well plates at a density of 1 × 105 cells/well. Twelve
hours after seeding, the cells were infected with MV-CEA
at an MOI of 0.1 for different time intervals and then
incubated with 20 μl of the methanethiosulfonate (MTS)
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was recorded using an enzyme-linked immunosorbent
assay (ELISA) plate reader.
Assessment of MV replication in human HB cells
Cells from the human Hep2G, HUH6 and L-02 cell lines
were seeded in 6-well plates at a density of 2.0 × 105
cells/well. Twelve hours after plating, the cells were
infected with each MV at an MOI of 0.1 in Opti-MEM I.
The cells and supernatants were collected at different
time intervals. The viruses were released by two cycles
of freezing and thawing. The viral titers in the cells and
supernatants were determined by CEA detection using a
CEA ELISA kit (PBL Biomedical Laboratories) as per the
manufacturer’s instructions.
CEA analysis
For the in vivo experiments, blood samples were col-
lected from mice by retro-orbital bleeding, and the
serum was analyzed to determine the CEA concentra-
tion. For the in vitro experiments, the supernatant from
the MV-CEA-infected and uninfected HB cells was col-
lected and analyzed to determine the CEA concentra-
tion. The ELISA specific for CEA was performed using
an ELISA kit (PBL Biomedical Laboratories) as per the
manufacturer’s instructions.
In vivo experiments
All procedures involving animals were approved by and
performed according to guidelines of the Institutional
Animal Care and Use Committee of the China Medical
University. A 27-gauge needle was used to subcutane-
ously inject nude mice (purchased from the laboratory
animal center of the China Medical University) with
5 × 106 Hep2G cells/100 μL PBS in the right flank. Mice
were examined daily for tumor growth. Tumor length,
width, and height were measured with calipers. Tumor
volume was calculated according to the formula width ×
width × height/2. When tumors reached a maximum
diameter of 0.5 cm, the MV-CEA and UV-inactivated
MV-CEA treatments were initiated by intratumoral in-
jection (n= 8 each group). Animals were euthanized
when the tumor diameter reached 1 cm or when 20% of
the body weight was lost.
Flow cytometry
The CD46 expression and the number of cells that died
by apoptosis were determined by flow cytometry. To
measure the CD46 expression, the cells were harvested
with Cell Dissociation Buffer (GIBCO, Invitrogen),
washed twice with PBS and incubated with a fluorescein
isothiocyanate–labeled monoclonal mouse antihuman
CD46, nectin 4 or isotype control antibodies (BD Bio-
sciences, Pharmingen, US) for 1 hour on ice. The cellswere washed twice with PBS. The cells were analyzed
(10,000 cells per sample) using a FACScan (BD Bio-
sciences, San Jose, CA). For the in vitro apoptosis assays,
HB cells were plated in 6-well plates and treated with
MV-CEA at an MOI of 0.1. Adherent and detached cells
were harvested at 24, 48 and 72 hours after infection by
centrifugation (1000 rpm) and were washed twice with
cold PBS. The cell pellet was re-suspended in 1× binding
buffer at a concentration of 1 × 106 cells/ml. A total of
100 μl of the cell suspension was transferred into a flow
cytometry tube. In the next step, 5 μl Annexin V-FITC
and 10 μl PI were added into the cell suspension fol-
lowed by gentle vortexing. The cells were incubated at
room temperature for 15 minutes in the dark. An add-
itional 400 μl of 1× binding buffer was added to each
tube. Finally, the cells were analyzed using cell Quest
software (BD Biosciences, San Jose, CA). All cells were
made within the scope of the axes, and the gates were
then set by drawing boundaries around the crowded
subsets with 105 cells that had an FSC-height >200
selected.
Western blot analysis and ELISA
Infected cells were harvested and solubilized in a Noni-
det P-40-based lysis buffer [20 mmol/L Tris (pH 7.4),
250 mmol/L NaCl, 1% Nonidet P-40, 1 mmol/L EDTA,
50 mg/ml leupeptin, and 1 mmol/L phenylmethylsulfo-
nyl fluoride]. After incubating the cells on ice for 5 min-
utes, the cell lysates were clarified by centrifugation at
13,000 g for 30 minutes at 4°C. The protein concentra-
tions in the lysates were quantified using the Multiskan
spectrum (Thermo Scientific, Finland). The samples
were separated on precast 4–12% gradient MOPS poly-
acrylamide gels (NOVEX, San Diego, CA) and then
transferred to nitrocellulose membranes (BIO-RAD,
Hercules, CA). The membranes were pretreated with
Tris-buffered saline (TBS) containing 5% dry milk and
0.05% Triton X-100 (TBST) for 1 hour at room
temperature and were then incubated with monoclonal
antiproteolytic cleavage of the poly(ADPribose) polymer-
ase (Biovision, Mountain View, CA) and rabbit anti-ß-
actin (CHEMICON International, Temecula, CA) anti-
bodies for 1 hour at room temperature. After several
washes in TBST, the membranes were probed with
rabbit or mouse peroxidase-conjugated secondary anti-
bodies (Santa Cruz Biotechnology, Santa Cruz, CA) at
room temperature for 1 hour. After a final wash with
TBST, the immune-reactivity of the blots was detected
using an enhanced chemiluminescence detection system
(Amersham, Piscataway, NJ).
Statistical methods
All the collected data were analyzed with SPSS13.0 soft-
ware. The statistical analysis of the significance of the
Zhang et al. BMC Cancer 2012, 12:427 Page 4 of 10
http://www.biomedcentral.com/1471-2407/12/427differences in survival between mice treated with recom-
binant MV-CEA and mice that did not receive MV-CEA
was performed using the log-rank test in the JMP (John
Macintosh Product) program. The analysis of flow cyto-
metry apoptosis comparisons used t test.The significance
level was set at p < 0.05.
Results
Overexpression of CD46 in human HB cells
The expression of CD46 in the human HB cell lines,
Hep2G and HUH6, and in the human normal liver cell
line L-02 was analyzed by flow cytometry with a FITC-
labeled monoclonal antihuman CD46 antibody. Human
HB cell lines express high levels of CD46 compared to
the normal liver cell line L-02. The CD46 receptor was
found in 90.82% of the Hep2G cells and 80.03% of the
HUH6 cells. A relatively low level of 8.91% was demon-
strated in L-02 (Figure 1).
MV-CEA induces significant CPEs and exhibits an
antitumor effect in human HB lines
To determine the infectivity of the recombinant MV-
CEA in human HB cells, the HB cell lines Hep2G and
HUH6 and the normal liver cell line L-02 were infected
with MV-CEA at MOIs of 1, 0.1 and 0.01 for 96 hours
and then stained with crystal violet. Cell viability after
MV-CEA infection was determined using the Cell-Titer
96 Aqueous Non-Radioactive Cell Proliferation Assay.
Analyses were performed every 24 hours for 96 hours.
MV-CEA demonstrated dramatic CPEs in an MOI-
dependent manner. The CPEs appeared at 72 hours post
infection with MV-CEA at an MOI of 0.1 in Hep2G and
HUH6 cells. However, the normal liver cell line L-02
showed minimal CPEs after MV-CEA infection
(Figure 2a).
Compared with the control, MV-CEA demonstrated a
greater reduction in the proliferation of Hep2G and
HUH6 cells from 72 to 96 hours at an MOI of 0.1. Re-
























Figure 1 Expression of the CD46 receptor in human HB cells and a no
in the human HB cell lines with the rate of 90.82% in Hep2G cells and 80.0
detected in L-02 cells. Analyses were performed by flow cytometry using aHUH6 cells within 72 hours after infection. Seventy-two
hours after infection, the viability of the Hep2G cells
was reduced to 74.67% at an MOI of 0.1 and to 86.33%
at an MOI of 0.01. The HUH6 cells yielded similar
results (Figure 2b).
MV-CEA successfully replicates in human HB cell lines and
induces cell lysis
Hep2G, HUH6 and L-02 cells were plated on 6-well
plates at a density of 2 × 105 cells/well. The cells were
infected with MV-CEA at an MOI of 0.1, and the super-
natants and cells were collected from 24 to 96 hours
postinfection. The intracellular viruses were released by
two cycles of freezing/thawing. CEA levels revealed a
time-dependent increase in MV mRNA in Hep2G and
HUH6 cells, but not in the L-02 cell line. The intracellu-
lar CEA level peaked at 72 hours postinfection in the
Hep2G and HUH6 cell lines (Figure 3a). In the culture
supernatant, the CEA level peaked at 84 hours post in-
fection (Figure 3b).
MV-CEA infection induces significant apoptosis in human
HB cell lines
Hep2G, HUH6 and L-02 cells were infected with MV-
CEA at an MOI of 0.1 and apoptotic cells, which also
had Annexin V-FITC staining, were analyzed by propi-
dium iodide staining and subsequent flow cytometry.
Upon infection with MV-CEA, the number of apoptotic
cells increased in a time-dependent manner. At an MOI
of 0.1, MV-CEA induced apoptosis in 7.67% and 15.8%
of the Hep2G cells and 7.3% and 17.35% of the HUH6
cells at 48 and 72 hours, respectively. However, at the
same MOI, MV-CEA induced apoptosis in fewer than
5% of the L-02 cells. The difference is statistically signifi-
cant between HB and L02 group (P < 0.05) but is not sta-
tistically significant between Hep2G and HUH6 cells
(P > 0.05), indicating that MV-CEA induces significant
apoptosis in human HB cells (Figure 4a,b). We further
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Figure 2 Infectivity, induction of syncytia, and CPE of MV-Edm
in human HB cells. (a) Serial analysis to determine the CPE of
recombinant MV-Edm was performed every 24 hours on the human
HB cell lines Hep2G and HUH6 and normal liver cell line L-02.
Seventy-two hours after infection at MOIs of 0.1 and 1, the cells
were stained with crystal violet representing viable, attached cells.
(b) The time course of cell viability of the human HB cell lines
Hep2G and HUH6 and normal liver cell line L-02 (n= 8) after
infection with recombinant MV-Edm at MOIs of 0.1 and 1 was
analyzed using a Cell Titer 96 Aqueous nonradioactive cell
proliferation assay kit. ***GroupMOI=1.0 versus Group MOI=0, P < 0.05; **
GroupMOI=0.1 versus Group MOI=0, P < 0.05. * GroupMOI=0.01 versus
Group MOI=0, P < 0.05.
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merase fragment was expressed in Hep2G cells at 48 h
and 72 h after being infected with MV-CEA. This find-
ing was in agreement with the FACS results (Figure 4c).
Intratumoral administration of MV-CEA induces
regression of HB xenografts and Can Be monitored by
serial serum CEA concentrations
To evaluate the potential use of recombinant MV-Edm
for HB therapy, we first tested MV-CEA in a subcutane-
ous human HB xenograft model. Hep2G cells (2 × 106
cells/mouse) were implanted in the right flanks of nude
mice. When the maximum tumor diameter measured ap-
proximately 0.5 cm, each mouse was treated with a total
of 5 doses of MV-CEA (1.0× 107 TCID50) or an equiva-
lent dose of UV-inactivated MV-CEA for 10 days (defined
as untreated, n= 8 per group). Serum CEA concentration,
tumor volume, and survival curves are shown in Figure 5.
In the Hep2G xenograft models, the serum CEA con-
centrations could be detected as early as 4 days after ini-
tiating therapy; these concentrations increased over
time. The CEA concentration reached its maximum on
day 25 after the last viral dose. After reaching their max-
imum concentrations, the mean CEA levels started to
decrease (Figure 5a). No CEA elevation was observed in
the UV-inactivated MV-CEA-treated (defined as un-
treated) animals.
In the Hep2G cell line xenografts, the tumor-suppressive
effect of MV-CEA first became apparent on day 7, and this
therapeutic efficacy then increased over time, resulting in
significant suppression of tumor growth and prolonged
survival of treated animals (Figure 5b,c). The median sur-
vival of those treated with MV-CEA and of those treated
with UV-inactivated MV-CEA was 72 and 25 days, re-
spectively. The median survival of the MV-CEA-treated
mice, with a 2.88-fold increase compared to the control
group, was significantly longer than that of the control
group (P< 0.05; Figure 5c). All mice in the control group
had to be euthanized on day 28. In the MV-CEA-treated
group, complete tumor regression was observed in
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Figure 3 Replication of MV-CEA in human HB cells. CEA level of the (a) intracellular and (b) culture supernatant in the Hep2G cell line was
detected by ELISA from 24 to 96 hours after infection at an MOI of 0.1. The intracellular CEA levels increased with time and peaked at 72 hours
post infection, and the supernatant CEA level peaked at 84 hours post infection in Hep2G cells but not in L-02 cells. This phenomenon provides
strong evidence for MV-CEA replication and cell lysis.
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Oncolytic therapy has reportedly excellent efficacy in the
treatment of many tumors, such as lymphoma, ovarian
cancer, mesothelioma, breast cancer and hepatocellular
carcinoma [9-15].. Specifically, there are many advan-
tages in using oncolytic therapy to treat liver malignan-
cies; at some medical centers, oncolytic therapy has even
been evaluated in clinical trials [37-39]. As a special sub-
type of hepatocellular carcinoma, HB originates from
the liver embryonic tissues and has the potential for di-
verse differentiation. Many components, such as the epi-
thelium, bone and cartilage, can be included within the
tumor; as a result, HB differs from general hepatocellular
carcinoma in its histological and the biological charac-
teristics. Histologically, the tumors are divided into epi-
thelial and mixed epithelial/mesenchymal subtypes.
Tumor cells may appear with a wide variety of charac-
teristics ranging from almost liver-cell-like to undifferen-
tiated blastomal cells. The majority of HB cells are
epithelial, consisting of embryonal and fetal cells. About
5% of the tumors belong to the small-cell undifferenti-
ated subtype, which is associated with a worse prognosis
[5,40]. Despite many advances in the use of oncolytic
therapies for other liver malignancies, little is known
about the use of oncolytic therapy in human HB. In this
study, we report the potent therapeutic efficacy of onco-
lytic virus against human HB cells.
Currently, a large variety of oncolytic viruses are under
evaluation in clinical trials [16-22]; the most common
viruses tested are derived from the attenuated Edmonston
vaccine strain of the measles virus [9-15], adenovirus
[16,17], herpes simplex virus (HSV) [18,19], Newcastle dis-
ease virus (NDV) [20], parvovirus [21], and poliovirus
[22]. The present results demonstrate that virotherapeutics
can be used safely and efficiently as cancer therapies. For
safety reasons, vaccine virus-derived virotherapeutics are
of special interest (e.g., measles vaccine virotherapeutics)because they are approved for human use, have been ap-
plied millions of times with a longstanding excellent safety
record, and exhibit a potent natural oncolytic activity
[41,42]. As one of the most tested vaccines, the attenuated
Edmonston vaccine strain of the measles virus has been
well reported in hepatocellular carcinoma but not in
HB treatment. MV is a replicating virus; therefore, the
MV-Edm vaccine strain derivatives of MV can offer the
potential advantage of increased dissemination in the
tumor and of potentially enhanced therapeutic benefit
compared to non-replicating viral or non-viral vector
systems.
The MV enters the cells through the interaction of the
H-glycoprotein with the MV receptors, CD150 (signaling
lymphocyte-activation molecule, SLAM) and CD46
[41-43]. Of note, the wild-type measles virus enters more
efficiently through the SLAM receptor, whereas the
Edmonston vaccine strain of measles virus enters
the cells predominantly through the CD46 receptor. The
MV receptor CD46 (membrane cofactor protein)
belongs to the family of membrane-associated comple-
ment regulatory proteins that serve as an important
mechanism of self-protection against complement-
mediated lysis. Tumor cells frequently overexpress
CD46. These mechanisms contribute to the tumor
selectivity of MV-Edm. The effectiveness of MV-Edm-
mediated oncolysis is highly dependent upon the expres-
sion of the cellular attachment receptor CD46, which is
expressed more frequently in human cancer cells than in
normal cells. In this study, we have demonstrated that
the measles virus vaccine strain derivative MV-CEA,
which has been genetically engineered to produce CEA,
has significant antitumor activity against HB as indicated
by the CPE of MV-CEA on HB cell lines in vitro and the
efficacy of MV-CEA in an HB xenograft model. Our data
show that CD46 is overexpressed in HB cell lines com-







































































































Figure 4 Apoptosis induced by MV-CEA in the human Hep2G and HUH6 cells. The cells were infected with MV-CEA at an MOI of 0.1.
Adherent and detached cells were harvested at 24, 48 and 72 hours post infection. (a) The percentage of apoptotic cells was measured by FACS
and is shown in this figure. In the L-02 cells, there was no dramatic apoptosis, but the Hep2G cells demonstrated dramatic apoptosis at 72 hours
postinfection. (b)The significant difference is significant between the HB and L-02 groups but not between the two HB cell lines. * Group Hep2G
Versus Group L-02, P < 0.01; **Group HUH-6 Versus Group L-02, P < 0.01. (c) We further examined the poly(ADP-ribose) polymerase expression by
Western blot and found that the 85-kd cleaved poly(ADP-ribose) polymerase fragment was expressed in the Hep2G and HUH-6 cells at 72 h after
infection with MV-CEA. This finding was in agreement with the FACS results.
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sion, syncytium formation, and tumor cell killing; there-
fore, we conclude that HB fulfills the requirements for
viral uptake and selective cell fusion and killing.
It is likely that additional factors contribute to the
MV-Edm tumor selectivity. In 2011, two independent
groups reported the identification of a novel MV-Edm
receptor, nectin 4 [44-46]. It is a tumor cell marker
found in breast, lung and ovarian carcinomas andrendered cells susceptible to the MV-Edm. The transient
knockdown of nectin 4 with siRNA abolished the wild-
type MV infection in these cell lines. Similar results were
also confirmed in the MV-Edm. The binding of the V
domain of nectin 4 to MV-H has been considered a po-
tential mechanism for the MV pathogenicity [44]. Also,
a few studies have indicated that MV infection can occur
via CD147 and virion-associated CypB, independent of
MV-H [47]. Watanabe et al [47]. identified CypB as a
Figure 5 The serum CEA concentrations and tumor suppression
after intratumoral MV-CEA therapy of human HB xenografts.
Mice bearing HB xenografts (Hep2G) were injected intratumorally
with 2 × 106 TCID50 of MV-CEA every other day a total of five times
(1.0 × 107 total TCID50/mouse). Treatment groups (n= 8 per group)
received active MV-CEA; the untreated group received
UV-inactivated MV-CEA. (a) The time course of serum CEA
concentration in HB xenograft-bearing mice after MV-CEA therapy.
*Group untreated versus Group treated, P < 0.05; (b) The increase in tumor
volume after initiation of the MV-CEA therapy. The data points are
given as the median with positive standard error. *Group untreated
versus Group treated, P < 0.05; (c) The Kaplan-Meier survival curves of the
treated and untreated mice. The results show significant suppression
of tumor growth in the MV-CEA treated animals (p<0.05) and
statistically significant prolongation of survival (p<0.05).
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wild-type MV recognizes CD147 as a receptor on epi-
thelial cells via the CypB that is incorporated into the
virus particles. It is still not clear whether other MV
strains, such as the MV-Edm, share a similar pathway.
Although a variety of other receptors including H pro-
tein dependent or independent ones can be used for
MV-Edm infection, it has been reported that their effi-
ciency is far lower than CD46 [46]. The CD46 receptor
is still the main player for MV-Edm spreading between
cells. Therefore, it is not necessary to detect all of the
other receptors one by one when a high level of CD46 is
sufficient for demonstrating the oncolytic mechanism.
MV-CEA resulted in a strong CPE in vitro and in vivo.
In this study, two human HB cell lines, Hep2G and
HUH6, were used. These two lines have features that are
the most characteristic of human HB and have been
widely used in HB-related investigations [40,48]. Al-
though the HB subtype and the risk level (either
standard-risk or high-risk) induced by these two lines
are still not verified, it is not critical for the oncolytic
virus to be used in the HB biotherapy. Only cells that
express high levels of the CD46 receptor are infected by
MV-Edm and lytically killed. This statement was verified
in the present study; both of the tested cell lines were
susceptible to the cytotoxic effect of MV-CEA but dif-
fered in their cell death kinetics. The Hep2G cells were
eliminated very efficiently and quickly, whereas the cyto-
toxic effect of MV-CEA on the HUH6 cells was
observed later. The HB cell lines used in our study
showed variable susceptibility to the cytotoxic effect of
MV-CEA, most likely resembling the situation in pri-
mary human tumors, which are composed of heteroge-
neous tumor cell populations [5]. Both cell lines express
comparable levels of CD46 but differ in other aspects,
such as their histological subtypes. Differences in the
components of these two lines or other not-yet-
identified factors in the process of measles-induced cyto-
toxicity could explain the differences in susceptibility.
As one of the most common causes of cell death, apop-
tosis has been well described in other malignancies. It has
been reported that MV-Edm can induce apoptosis in both
the tumor cells and the syncytia by a series of signal path-
ways, such as the Fas-associated death domain (FADD),
protein kinase C (PKC), and the janus kinase-signal trans-
ducer and activator of transcription (JAK-STAT) signaling
pathways [49,50]. Similarly, we have used a variety of tech-
niques that demonstrate extensive apoptosis after infec-
tion of MV-Edm in human HB cell lines [26]. These
results are in agreement with prior work that has indi-
cated that apoptosis is the main mechanism of death for
MV-induced syncytia [51]. The exact mechanism of cell
death after MV-Edm-induced syncytium formation is still
unknown and should be further investigated.
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human HB is that the tumor offers the possibility of loca-
lized treatments compared with other malignancies such
as ovarian cancers, glioblastoma and prostate cancers. In
most cases of HB, the tumor is located within the liver
and does not have distant metastases after regular chemo-
therapy; also, the tumor is easily accessible using ultra-
sound or computed tomography (CT) guidance. HB
tumors can easily be localized and injected with a thera-
peutic agent. In any case, the presence of anti-MV anti-
bodies is not expected to significantly decrease efficacy. In
a mouse model in which mice received passive transfer of
anti-MV antibodies, Grote et al. found that intratumoral
MV-Edm therapy of human lymphoma xenografts
resulted in effective tumor regression without comprom-
ise through the presence of anti-MV antibodies [52].
These findings were in accordance with the results of a
study of intratumoral therapy with a retrovirus in
immune-competent C3H mice and of a clinical phase II
study of a genetically modified adenovirus in patients with
advanced head and neck cancer [53,54].
A major drawback of many cancer agents is the lack of
convenient methods for monitoring the agent after ad-
ministration to the patient. MV-Edm derivatives engi-
neered to express CEA allow noninvasive tracking of the
viral gene expression as well as localization of the
infected tumor tissue. The advantage of this method has
been well described in previous investigations [15,33]. In
this study, the same result was verified in HB both
in vitro and in vivo. Given the fact that Hep2G is known
to intrinsically produce CEA, these cells themselves may
be the source of the CEA, which would impact the
serum CEA. However, the impact on the final result
would be minor because all of the comparisons were
carried out within the Hep2G groups instead of between
the Hep2G and other groups. In addition, in the clinical
practice, fewer than 10% of patients with HB can pro-
duce CEA and the amount is very little; it is likely un-
necessary to worry about the confusion of intrinsic CEA.Conclusions
MV-CEA has potent therapeutic efficacy against human
HB both in vivo and in vitro. We therefore believe that,
given their antitumor activity and potential for noninva-
sive monitoring, engineered trackable MV derivatives
warrant further investigation for their use in HB treat-
ment. These studies have not yet been translated into a
clinical trial, but should provide the foundation for
future clinical developments.
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